US Capitol Capsule: Drug price 'yellow' signs: market canaries or lemons?
This article was originally published in Scrip
Executive Summary
The "troubling" trends in the rising costs to US consumers of prescription drugs, including generics, is a big yellow warning sign the biopharmaceutical market is out of balance, largely due to a lack of transparency in how medicines are priced, insisted Dr Stephen Schondelmeyer, a professor of pharmaceutical management and economics and director of the PRIME Institute at the University of Minnesota.